CClinicalTrials.gg
Status unknownNCT04770415Updated Feb 25, 2021

Ophthalmic Manifestations of Patients With Mucopolysaccharidosis

An observational study in Ophthalmic Manifestations, sponsored by Shrouk Shaban Bakr. Status unknown at 1 site in Egypt. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2021-02-25.

Sponsored by Shrouk Shaban Bakr · Observational

The sponsor has not verified this record recently (last verified Feb 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
28
Ages
Up to 18 Years
Sex
All
01

Study summary

Mucopolysaccharidosis (MPSs) are a group of disorders caused by inherited defects in lysosomal enzymes resulting in widespread intra- and extra-cellular accumulation of glycosaminoglycan(1,2). They have been subdivided according to enzyme defect and systemic manifestations and include MPS IH (Hurler)(3) , MPS IS (Scheie), MPS IH/S (Hurler/Sheie), MPS II(4,5) (Hunter), MPS III (Sanfilippo)(6) , MPS IV (Morquio)(7,8), MPS VI (Maroteaux-Lamy)(9), MPS VII (Sly)(10,11) and MPS IX (Natowicz)(12). Mucopolysaccharidosis have a spectrum of systemic manifestations, including airway and respiratory compromise, skeletal deformities, intellectual and neurological impairment, cardiac abnormalities, gastrointestinal problems and ocular manifestations(13). Ocular manifestation are common in the mucopolysaccharidosis and may result in significant visual impairment(14). Corneal opacification of varying severity is frequently seen, as well as retinopathy, optic nerve swelling and atrophy, ocular hypertension, and glaucoma(14). New treatment modalities for the systemic manifestations of the mucopolysaccharidosis include bone marrow transplant and enzyme replacement therapy have resulted in an improved prognosis in many cases(15).

02

Conditions studied

  • Ophthalmic Manifestations

Browse trials for

03

In context

Mucopolysaccharidoses

145 studies on the registry are indexed under Mucopolysaccharidoses; 11 are open to participants now.

This study's planned enrollment of 28 is below the median of 32 across 56 observational studies indexed under Mucopolysaccharidoses.

Browse Mucopolysaccharidoses studies →

Lead sponsor

This is the only study on the registry with Shrouk Shaban Bakr as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients at any age up to 18 years with any type of MPS

Inclusion criteria

  • All patients at any age up to 18 years with any type of MPS confirmed by the enzymatic assay

Exclusion criteria

Exclusion Criteria:

  • Any patient other than MPS
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
28 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. early detection and management of ophthalmic manifestations in patients with MPS

    Time frame: 1 week

07

Study locations

1 of 1 sites recruiting
  • Assiut University
    Assiut, 71717, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04770415
Lead sponsor
Shrouk Shaban Bakr
Responsible party
Shrouk Shaban Bakr (Resident doctor, Assiut University) — Sponsor-investigator
First posted
Feb 25, 2021
Start date
Apr 1, 2021 (estimated)
Primary completion
Apr 1, 2023 (estimated)
Completion
Apr 1, 2023 (estimated)
Last update
Feb 25, 2021

Study contacts

Shrouk Shaban Bakr, Resident doctor
Contact
sshrouk617@gmail.com
01069759819

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion